Hereditary Breast and Ovarian Cancer: Molecular Mechanism and Clinical Practice
Editat de Seigo Nakamura, Daisuke Aoki, Yoshio Mikien Limba Engleză Hardback – 21 oct 2021
Toate formatele și edițiile | Preț | Express |
---|---|---|
Paperback (1) | 721.56 lei 17-23 zile | +63.21 lei 5-11 zile |
Springer Nature Singapore – 22 oct 2022 | 721.56 lei 17-23 zile | +63.21 lei 5-11 zile |
Hardback (1) | 1082.46 lei 22-36 zile | |
Springer Nature Singapore – 21 oct 2021 | 1082.46 lei 22-36 zile |
Preț: 1082.46 lei
Preț vechi: 1139.43 lei
-5% Nou
Puncte Express: 1624
Preț estimativ în valută:
207.16€ • 215.19$ • 172.08£
207.16€ • 215.19$ • 172.08£
Carte disponibilă
Livrare economică 13-27 ianuarie 25
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9789811645204
ISBN-10: 9811645205
Pagini: 324
Ilustrații: VIII, 324 p. 31 illus., 24 illus. in color.
Dimensiuni: 155 x 235 mm
Greutate: 0.68 kg
Ediția:1st ed. 2021
Editura: Springer Nature Singapore
Colecția Springer
Locul publicării:Singapore, Singapore
ISBN-10: 9811645205
Pagini: 324
Ilustrații: VIII, 324 p. 31 illus., 24 illus. in color.
Dimensiuni: 155 x 235 mm
Greutate: 0.68 kg
Ediția:1st ed. 2021
Editura: Springer Nature Singapore
Colecția Springer
Locul publicării:Singapore, Singapore
Cuprins
1 History, Advancements, and Future Strategies.- 2 Molecular basis of BRCA1 and BRCA2 - Homologous recombination deficiency and tissue-specific carcinogenesis.- 3 Genetic Testing.- 4 Variants of uncertain significances in hereditary breast and ovarian cancer.- 5 Genetic counseling in Hereditary Breast and Ovarian Cancer.- 6 Hereditary Breast Cancer.- 7 Hereditary Ovarian Cancer.- 8 Risk-Based Breast Cancer Screening.- 9 Chemoprevention for Breast Cancer.- 10 Chemoprevention for Ovarian Cancer.- 11 Risk-Reducing Mastectomy (RRM).- 12 Risk-reducing salpingo-oophorectomy (RRSO).- 13 Panel Testing.- 14 Germline Findings through Precision Oncology for Ovarian Cancer.- 15 Germline Findings from Genetic Testing for Breast Cancer.- 16 Hereditary Breast and Ovarian Cancer (HBOC) Database.- 17 Ethical Issues: Overview in Genomic analysis and Clinical Context.- 18 PARP Inhibitors-Mechanism of action.- 19 PARPi - Efficacy in Hereditary Breast Cancer.- 20 Efficacy of Poly ADP-Ribose Polymerase Inhibitors for Hereditary Ovarian Cancer.
Notă biografică
Seigo Nakamura
Department of Breast Surgical Oncology
Showa University, School of Medicine
Tokyo, Japan
Daisuke Aoki
Department of Obstetrics and Gynecology,
Keio University School of Medicine,
Tokyo, Japan
Yoshio Miki
Department of Molecular Genetics, Medical Research Institute,
Tokyo Medical and Dental University,
Tokyo, Japan
Showa University, School of Medicine
Tokyo, Japan
Daisuke Aoki
Department of Obstetrics and Gynecology,
Keio University School of Medicine,
Tokyo, Japan
Yoshio Miki
Department of Molecular Genetics, Medical Research Institute,
Tokyo Medical and Dental University,
Tokyo, Japan
Textul de pe ultima copertă
This highly informative and clearly written book presents the basic science and the latest data on hereditary breast and ovarian cancer (HBOC) to provide an up-to-date and holistic overview of the disease. It starts off by presenting the molecular mechanisms, genetic testing and counseling, and variants of unknown significance (VUS) to help readers understand the contemporary interpretation of the disease. Further chapters focus on the surveillance, diagnosis and treatment, including chemoprevention, risk reduction and drug development based on molecular mechanisms. It also includes a chapter on the latest findings from the HBOC database, ethical issues and the parp inhibitors, and discusses innovative thinking to manage and understand the disease.
Hereditary Breast and Ovarian Cancer - Molecular Mechanism and Clinical Practice offers breast surgeons, medical oncologists, gynecological oncologists and genetic counselors a comprehensive overview of the disease.Providing insights into recent scientific findings and further avenues for investigation, it is also a thought-provoking and informative read for researchers and scholars.
Caracteristici
Discusses the molecular mechanisms, genetic testing and counseling, and variants of unknown significance Includes a special chapter on the recent findings from the HBOC database, ethical issues and the parp inhibitors Appeals to breast surgeons, medical oncologists, gynecological oncologists and genetic counselors